Sangamo Therapeutics, Inc (SGMO) — SEC Filings
Sangamo Therapeutics, Inc (SGMO) — 38 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 19 8-K, 10 SC 13G/A, 5 10-Q.
View Sangamo Therapeutics, Inc on SEC EDGAR
Overview
Sangamo Therapeutics, Inc (SGMO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: SANGAMO THERAPEUTICS, INC. (SGMO) reported a significant decline in revenue and a substantial net loss for the three and nine months ended September 30, 2025. Revenue plummeted to $581 thousand for the three months ended September 30, 2025, a drastic 98.8% decrease from $49.412 million in the same p
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 2 bullish, 6 bearish, 29 neutral, 1 mixed. The dominant filing sentiment for Sangamo Therapeutics, Inc is neutral.
Filing Type Overview
Sangamo Therapeutics, Inc (SGMO) has filed 5 10-Q, 19 8-K, 2 DEF 14A, 2 10-K, 10 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of SGMO's 28 recent filings, 4 were flagged as high-risk, 15 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $581 thousand |
| Net Income | $(34,930) thousand |
| EPS | $(0.11) |
| Debt-to-Equity | 13.2 |
| Cash Position | $29,616 thousand |
| Operating Margin | -6151.6% |
| Total Assets | $88,643 thousand |
| Total Debt | N/A |
Industry Context
Sangamo Therapeutics operates in the highly competitive and rapidly evolving gene therapy and gene editing sector. This industry is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Companies in this space often rely on strategic partnerships and substantial funding to advance their pipelines through clinical trials and towards commercialization.
Top Tags
biotech (5) · institutional-ownership (5) · Biotechnology (4) · corporate-governance (4) · amendment (4) · Gene Therapy (3) · delisting (3) · regulatory (3) · 8-k (3) · 10-Q (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue (in thousands) | $581 | for the three months ended September 30, 2025, a 98.8% decrease from 2024 |
| Net loss (in thousands) | $(34,930) | for the three months ended September 30, 2025, compared to net income of $10,672 thousand in 2024 |
| Cash and cash equivalents (in thousands) | $29,616 | as of September 30, 2025, down from $41,918 thousand at December 31, 2024 |
| Shares outstanding | 336,494,489 | as of November 4, 2025 |
| Basic net loss per share | $(0.11) | for the three months ended September 30, 2025 |
| SEC File Number | 000-30171 | Identifies the company's filings with the SEC. |
| Q2 2025 Net Loss | $75.2M | Increased from $60.5M in Q2 2024, indicating widening losses. |
| Q2 2025 Revenue | $15.8M | Decreased 28.5% from $22.1M in Q2 2024, showing revenue decline. |
| YTD 2025 Net Loss | $148.1M | Widened from $120.3M in YTD 2024, reflecting sustained unprofitability. |
| YTD 2025 Revenue | $30.1M | Decreased from $45.6M in YTD 2024, highlighting a significant revenue drop. |
| Cash & Equivalents | $150.3M | As of June 30, 2025, down from $200.5M at Dec 31, 2024, indicating cash burn. |
| Capital Raised YTD | $20.1M | Through At-The-Market offering, showing reliance on equity financing. |
| Increase in Q2 Net Loss | 24.3% | Percentage increase from Q2 2024 to Q2 2025. |
| Decrease in Q2 Revenue | 28.5% | Percentage decrease from Q2 2024 to Q2 2025. |
| Commission File Number | 000-30171 | Identifies the company's SEC filing record. |
Forward-Looking Statements
- {"claim":"Vanguard will maintain a significant, albeit potentially adjusted, stake in Sangamo Therapeutics over the next year.","entity":"The Vanguard Group","targetDate":"2025-02-13","confidence":"high"}
- {"claim":"Biogen's reduced stake could lead to a short-term dip in Sangamo's stock price.","entity":"Sangamo Therapeutics, Inc.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"Wasatch Advisors LP will maintain a significant stake in Sangamo Therapeutics for the foreseeable future.","entity":"Wasatch Advisors LP","targetDate":"12-24 months","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Sangamo Therapeutics, Inc (SGMO)?
Sangamo Therapeutics, Inc has 38 recent SEC filings from Jan 2024 to Nov 2025, including 19 8-K, 10 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SGMO filings?
Across 38 filings, the sentiment breakdown is: 2 bullish, 6 bearish, 29 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Sangamo Therapeutics, Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Sangamo Therapeutics, Inc (SGMO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Sangamo Therapeutics, Inc?
Key financial highlights from Sangamo Therapeutics, Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SGMO?
The investment thesis for SGMO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Sangamo Therapeutics, Inc?
Executive information for Sangamo Therapeutics, Inc is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Sangamo Therapeutics, Inc stock?
Of SGMO's 28 assessed filings, 4 were flagged high-risk, 15 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Sangamo Therapeutics, Inc?
Recent forward-looking statements from Sangamo Therapeutics, Inc include guidance on {"claim":"Vanguard will maintain a significant, albeit potentially adjusted, stake in Sangamo Therapeutics over the next and 2 other predictions.